SMARCA4 and sarcoma: Some exhibit SMARCA4 deficiency or TP53 mutations, as reported in a 2020 NIH study [77,78], while others lack these alterations but do not demonstrate known ESS-related fusions such as JAZF1 or NTRK, which are used diagnostically to exclude other specific sarcoma types [68,74].